These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32050011)

  • 1. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
    Aungsumart S; Apiwattanakul M
    PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.
    Aungsumart S; Turongkaravee S; Youngkong S; Apiwattanakul M; Thakkinstian A; Chaikledkaew U
    BMC Health Serv Res; 2023 Oct; 23(1):1096. PubMed ID: 37833729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
    Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
    Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
    Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
    BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
    Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
    BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
    Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
    J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility of Video-Electroencephalography Monitoring Followed by Surgery in Adults with Drug-Resistant Focal Epilepsy in Thailand.
    Kitwitee P; Unnwongse K; Srikijvilaikul T; Yadee T; Limwattananon C
    World Neurosurg; 2017 Feb; 98():750-760.e3. PubMed ID: 27913266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
    JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
    Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
    Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
    BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.